Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
The Global Respiratory Syncytial Virus (RSV) Therapeutics Market has exhibited significant growth, reaching USD 1.2 billion in 2022, with projections to grow further to USD 2.4 billion by 2030, driven by a notable CAGR of 10.2% during the forecast period (2023-2030). Factors contributing to this expansion include the increasing elderly population, rising RSV infections in infants and young children, availability of improved treatment options, and the presence of numerous hospitals and specialty clinics.

Market Dynamics:

Increasing RSV Prevalence: RSV is a prevalent respiratory virus affecting young children and older individuals, causing respiratory diseases like bronchiolitis and pneumonia. The substantial prevalence, including 58,000 hospitalizations of infants and 14,000 deaths in the US annually, contributes to market growth.

Clinical Trials Driving Growth: The rise in clinical trials by key players, resulting in successful outcomes like Sanofi and AstraZeneca's Nirsevimab, reducing RSV hospitalizations by 83%, is propelling market expansion.

High Disease Management Costs: The substantial cost associated with managing RSV, especially immunoprophylaxis with palivizumab, is expected to impede market growth.

Request For Free Sample: https://www.datamintelligence.com/download-sample/respiratory-syncytial-virus-therapeutics-market

Segmentation Analysis:

Nirsevimab Dominance: Nirsevimab, a monoclonal antibody targeting RSV, holds the largest market share (31.20% in 2022) due to its effectiveness in preventing RSV-related hospitalizations in newborns and infants. Approvals by regulatory bodies contribute to its dominance.

Geographical Insights:

North America's Dominant Position: North America, holding approximately 39.4% of the total market share, experiences a growing RSV burden, leading to increased research, investments, and demand for diagnostics.
Key Players:

Major global players in the market include Sanofi, GSK plc, Pfizer, AstraZeneca, AbbVie, Bausch Health Companies, among others.

COVID-19 Impact:

Russia-Ukraine War Impact: Anticipated minimal impact on the global RSV market due to low prevalence and absence of key market players in the region. Potential effects on import/export of materials, tests, and devices might have limited influence.

Artificial Intelligence Impact: AI's positive impact is expected in aiding detection and diagnosis of RSV-related lung abnormalities through analysis of medical imaging data, facilitating early diagnosis and intervention.

The market is driven by factors such as increasing RSV prevalence, successful clinical trials of therapeutics, and dominance of drugs like Nirsevimab. However, the high cost of disease management and treatment might impede market expansion. Geographically, North America leads due to the rising burden of RSV infections. Major players continue to drive market growth through innovative drug developments and regulatory approvals.

Related Topics
https://www.datamintelligence.com/download-sample/lower-respiratory-tract-therapeutics-market
https://www.datamintelligence.com/download-sample/-respiratory-monitoring-market
https://www.datamintelligence.com/research-report/respiratory-infectious-disease-diagnostics-market
https://www.datamintelligence.com/research-report/respiratory-inhalers-market

Media Contact
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.